Works matching IS 13518216 AND DT 2024 AND VI 30 AND IP 1
Results: 27
Issue Information.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 1, doi. 10.1111/hae.14938
- Publication type:
- Article
Occupational therapy in the management of haemophilia patients: A scoping review.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 51, doi. 10.1111/hae.14913
- By:
- Publication type:
- Article
Gene therapy for haemophilia A and B, from basic principles to clinical implementation: An illustrated review.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 5, doi. 10.1111/hae.14907
- By:
- Publication type:
- Article
Hybrid human‐porcine factor VIII proteins partially escape the inhibitory effects of anti‐factor VIII inhibitor alloantibodies having A2 or C2 domain specificity.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 140, doi. 10.1111/hae.14911
- By:
- Publication type:
- Article
Observational cohort study of long‐term outcomes of liver transplantation in haemophilia.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 87, doi. 10.1111/hae.14910
- By:
- Publication type:
- Article
A single‐centre experience of 29 total ankle replacement in haemophiliac patients: Therapeutic management, factor consumption and cost.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 204, doi. 10.1111/hae.14909
- By:
- Publication type:
- Article
Perspectives and perception of haemophilia gene therapy by French patients.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 68, doi. 10.1111/hae.14908
- By:
- Publication type:
- Article
Landmark endorsement of a global registry: The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), publicly endorses World Federation of Hemophilia Gene Therapy Registry as global standard.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 232, doi. 10.1111/hae.14912
- By:
- Publication type:
- Article
Management strategies in persons with inherited haemophilia requiring antithrombotic therapy: A scoping review.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 16, doi. 10.1111/hae.14906
- By:
- Publication type:
- Article
Iron overload causes macrophages to produce a pro‐inflammatory phenotype in the synovium of hemophiliac arthritis via the acetyl‐p53 pathway.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 195, doi. 10.1111/hae.14905
- By:
- Publication type:
- Article
Outcomes of total hip and knee arthroplasty in patients with haemophilia: A meta‐analysis of comparative studies and clinical practice recommendations.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 180, doi. 10.1111/hae.14904
- By:
- Publication type:
- Article
Association of bone mineral density and potential risk factors for osteoporosis in patients with severe haemophilia A.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 130, doi. 10.1111/hae.14903
- By:
- Publication type:
- Article
Coagulation potentials of plasma‐derived factors VIIa and X mixture (Byclot<sup>®</sup>) evaluated by global coagulation assay in patients with acquired haemophilia A.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 249, doi. 10.1111/hae.14902
- By:
- Publication type:
- Article
Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 161, doi. 10.1111/hae.14901
- By:
- Publication type:
- Article
A pilot study of US HTC physical therapists' concordance of PT MASAC recommendations and educational needs.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 169, doi. 10.1111/hae.14900
- By:
- Publication type:
- Article
Health‐related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study).
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 98, doi. 10.1111/hae.14899
- By:
- Publication type:
- Article
Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 123, doi. 10.1111/hae.14898
- By:
- Publication type:
- Article
Direct data transfer of people with hereditary bleeding disorders from the Thai haemophilia treatment centre registry to the Annual Global Survey of the World Federation of Hemophilia.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 245, doi. 10.1111/hae.14897
- By:
- Publication type:
- Article
Unravelling the effect of blood group on FVIII:C levels and response to DDAVP in 20 males with a single genotype (Twillingate Variant) causing Haemophilia A.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 116, doi. 10.1111/hae.14896
- By:
- Publication type:
- Article
Association of patient, treatment and disease characteristics with patient‐reported outcomes: Results of the ECHO Registry.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 106, doi. 10.1111/hae.14895
- By:
- Publication type:
- Article
Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 59, doi. 10.1111/hae.14894
- By:
- Publication type:
- Article
Blue toe syndrome, severe haemophilia A and emicizumab.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 241, doi. 10.1111/hae.14893
- By:
- Publication type:
- Article
In vitro field study and worldwide survey assessing how clinical haemostasis laboratories analyse recombinant and plasma‐derived von Willebrand factor products.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 151, doi. 10.1111/hae.14892
- By:
- Publication type:
- Article
Two‐center validation of assays for the detection of binding and neutralizing anti‐factor VIII antibodies.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 224, doi. 10.1111/hae.14885
- By:
- Publication type:
- Article
Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 75, doi. 10.1111/hae.14882
- By:
- Publication type:
- Article
An open‐label, multi‐centre, post‐marketing study to assess the efficacy and safety of a plasma‐derived VWF/FVIII concentrate in patients with von Willebrand disease.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 236, doi. 10.1111/hae.14868
- By:
- Publication type:
- Article
A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one‐stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 214, doi. 10.1111/hae.14831
- By:
- Publication type:
- Article